- Trial Phase
- Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- Time to Market
- Already approved and commercialized since 2017
- Why 4/10
- Dupixent is already approved and marketed across 9 indications with $17.8B in 2025 global net sales. No pending PDUFA or binary regulatory decision in the next ~12 months. The next catalysts are Phase 3 readouts for Lichen Simplex Chronicus (STYLE 1/STYLE 2, estimated primary completion June 2026) and potential label expansion filings, which are not binary approval events. As an approved mega-blockbuster, the stock-moving binary already passed years ago; the drug drives steady revenue growth rather than a single headline catalyst.
Dupixent is Regeneron's most important revenue driver, generating collaboration revenue that rose 14-18% YoY in recent quarters. Investors should watch for the STYLE 1/STYLE 2 Phase 3 topline readouts for Lichen Simplex Chronicus (mid-2026) as the next label-expansion catalyst, but the main investor focus should be on Dupixent's patent cliff — earliest key patents begin expiring around 2027-2031, which will determine whether Regeneron can defend its ~$17.8B+ franchise against biosimilar entry.
Price Chart
Executive Summary
Dupixent (dupilumab) is a blockbuster injectable biologic co-developed and co-commercialized by Regeneron (REGN) and Sanofi (SNY). First approved in 2017 for atopic dermatitis, it is now FDA-approved for 9 indications spanning dermatology, respiratory, and gastroenterology — including the landmark COPD approval in September 2024. Global net sales reached ~$17.8 billion in 2025 (up 26% YoY), and it is widely considered one of the best-selling drugs in the world. For Regeneron, Dupixent is the primary growth engine, with the company recording collaboration revenue of $2.06 billion from Sanofi in H1 2025 (up 18% YoY). The bull case centers on continued label expansion into large markets like COPD and chronic urticaria, with peak sales estimates exceeding $22 billion. The bear case centers on imminent patent expiration (earliest patents 2027-2031), potential biosimilar competition from Amgen and others, safety litigation around a potential T-cell lymphoma signal, and competitive pressure from next-gen IL-13 inhibitors like Eli Lilly's lebrikizumab.
How It Works
Dupixent is an injectable biologic drug (a monoclonal antibody) that blocks two specific inflammatory signals in the body called IL-4 and IL-13. By blocking these signals, it calms down a type of allergic inflammation (called "type 2 inflammation") that drives a range of conditions — from eczema and asthma to nasal polyps, food allergies in the esophagus, COPD exacerbations, and chronic hives. Think of it as damping down an overactive allergic fire across multiple organs.
Trial Status
Dupixent is FDA-approved for 9 indications as of early 2026: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, COPD (approved Sept 2024), chronic spontaneous urticaria (CSU) in adults/adolescents (April 2025) and children aged 2-11 (April 2026), bullous pemphigoid (June 2025), and allergic fungal rhinosinusitis / AFRS (Feb 2026). Ongoing Phase 3 trials include STYLE 1 and STYLE 2 for Lichen Simplex Chronicus (estimated primary completion June 2026). A Phase 2 trial for ulcerative colitis (LIBERTY-UC SUCCEED) has estimated primary completion May 2026.
The Two-Sided Case
Upcoming Catalysts
- STYLE 1 / STYLE 2 Phase 3 topline results for Lichen Simplex Chronicus (LSC) — estimated primary completion June 2026
- LIBERTY-UC SUCCEED Phase 2 results for ulcerative colitis — estimated primary completion May 2026
- Potential sBLA filing for LSC if Phase 3 data is positive — could lead to a 10th FDA-approved indication
- Patent litigation developments — any Amgen biosimilar challenge or Sanofi/Regeneron defensive patent suit updates
- Quarterly collaboration revenue reports — Dupixent's growth trajectory in COPD and CSU will be key earnings drivers
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report